SEC Charges New York-Based Fund Manager with Conducting

New Post Public Reply Private Reply Replies (0) Message Board
MaxShockeR

SEC Charges New York-Based Fund Manager with Conducting Fraudulent Trading Schemes

FOR IMMEDIATE RELEASE 2012-261

Washington, D.C., Dec. 11, 2012 — The Securities and Exchange Commission today charged a New York-based fund manager with conducting a pair of illegal trading schemes to financially benefit his investment fund Octagon Capital Partners LP.


Additional Materials


The SEC alleges that Steven B. Hart made $831,071 during a four-year period through illicit trading while he also worked as a portfolio manager and employee at a New Jersey-based firm that served as an adviser for several affiliated investment funds.  In one scheme, Hart illegally matched 31 pre-market trades to benefit his own fund at the expense of one of his employer’s funds.  In the other scheme, Hart conducted insider trading in the securities of 19 issuers based on nonpublic information he learned in advance of their offering announcements. Furthermore, Hart signed two securities purchase agreements in which he falsely represented that he had not traded the issuer's securities prior to the public announcement of the offerings in which he had been confidentially solicited to invest.

Hart agreed to pay more than $1.3 million to settle the SEC’s charges.

“By engaging in more than 50 instances of illegal activity in his securities trading, Hart showed a complete disregard for the securities laws and our markets,” said Andrew M. Calamari, Director of the SEC’s New York Regional Office.  “Hart also misused his position of authority as a portfolio manager of his employer’s fund in order to make handsome profits for his own fund.”

According to the SEC’s complaint filed in U.S. District Court for the Southern District of New York, Hart conducted his schemes from 2007 to 2011.  He caused Octagon to purchase stock in small, thinly traded issuers at the going market price so that he could sell the same stock the following day to his employer’s fund at a price substantially above the prevailing market price.  Each of the sales from Octagon to the employer’s fund occurred in pre-market trading, thus Hart was able to ensure that the trades matched.  Later that same day or within a few days of the matched trades, Hart directed the employer’s fund to sell the recently-acquired stock on the open market at a loss.  Hart generated ill-gotten gains of $586,338 for Octagon in this scheme.

According to the SEC’s complaint, Hart was confidentially solicited by 19 issuers to invest in securities offerings where he expressly agreed to go “over-the-wall” and keep confidential the information he received and not trade on it.  Nevertheless, Hart traded for Octagon on the basis of material nonpublic information about the offerings in breach of his duty of trust or confidence.  Hart’s illegal trades involved PIPE offerings, registered direct offerings, and confidentially marketed public offerings.  Octagon derived ill-gotten gains of $244,733 as a result of Hart’s misconduct.

The SEC alleges that in order to induce two issuers to sell securities to his fund, Hart signed securities purchase agreements falsely representing that Octagon had not traded the issuers’ securities after he had been solicited.  Despite going “over-the-wall” during the solicitations conducted by the two issuers, Hart directed short sales of these issuers’ securities and obtained insider trading profits.  He subsequently signed the securities purchase agreements misrepresenting that he hadn’t traded in their securities in the days leading up to the public announcements about the offerings.

The SEC’s complaint against Hart alleges violations of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934, and Rule 10b-5, and Sections 206(1) and 206(2) of the Investment Advisers Act of 1940.  Hart agreed to pay $831,071 in disgorgement, $103,424 in prejudgment interest, and a $394,733 penalty to settle the SEC’s charges without admitting or denying the allegations.  Hart also consented to the entry of a judgment enjoining him from future violations of the respective provisions of the Securities Act, Exchange Act, and Advisers Act.  The settlement is subject to court approval.

The SEC’s investigation was conducted in the New York Regional Office by Celeste A. Chase, Eduardo A. Santiago-Acevedo, and Osman E. Nawaz with assistance from Frank J. Milewski.  The SEC acknowledges the assistance of the Financial Industry Regulatory Authority (FINRA) in this matter.

# # #

Source http://www.sec.gov/news/press/2012/2012-261.htm

#CorpRedFlags #ScamBusters

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novartis Pulls the Plug on BioArctic Agreement

Updated Category News Views 57

Novartis Drops BioArctic Like a Hot Potato Well, folks, it looks like Novartis has decided to pack up its bags and hightail it out of its collaboration with BioArctic AB. This ain't just any small piece of news—it's got ramifications that have folks in the biotech and healthcare sector scratching their heads and, probably, feeling a mixture of apprehension and...

Continue Reading
NABEP Powers Ahead with Orinoco Furnace Restart

Updated Category News Views 142

Revving Up the Engines in the Orinoco Belt And HERE we are again, ringing the bell on another bold move in the world of energy. NABEP is pulling back the curtain on their revamped activities in the Orinoco Belt. You're telling me they just fired up one heck of a furnace? In this relentless pursuit to spike their output, you've gotta respect the hustle. It's like cranking...

Continue Reading
Differentia Bio's AI: Transforming Drug Development Dynamics

Updated Category News Views 51

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Continue Reading
Business Formations in 2026: A Blow-by-Blow Analysis

Updated Category News Views 47

Surging Entrepreneurial Spirit in 2026 Just when you’d think economic jitters would slow us down, American entrepreneurship is out there smashing records like a bulldozer through a picket fence. September 2026 saw a staggering 562,579 new business formations—the highest September tally ever logged. That's no fluke. This momentum hasn’t let up all year, and it paints...

Continue Reading
TEKLYNX 2026: Revolutionizing Barcode Labeling Tech

Updated Category News Views 40

In the ever-evolving world of supply chain technology, a big move by TEKLYNX is making waves. The 2026 version of their barcode labeling software isn't just an upgrade—it's a full-blown transformation. They've fine-tuned their suite to align with the latest industry standards and integrated fresh capabilities that scream future-proofing. TEKLYNX's Game-Changing Upgrades...

Continue Reading
Hunan Courts European Investors with Strategic Initiatives

Updated Category News Views 74

Seizing the European Spotlight You've heard of places making a splash, but Hunan smashing through the scene in Europe? Now that's a move you don't see every day. This Chinese province is dead set on stealing the European investment show, with a slick meet-and-greet tour across Germany and Switzerland. What's cooking in Hunan isn't your typical rice porridge—it's a...

Continue Reading
Waters Acquires MOBILion: Ion Mobility Meets AI

Updated Category News Views 18

MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...

Continue Reading
KOVE's Bold Lineup Expansion at EICMA 2026

Updated Category News Views 0

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Continue Reading
Qapture's Institutional Stablecoin Venture Unveiled

Updated Category News Views 26

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...

Continue Reading
How Octopus AI Reinvents Financial Processes in 2026

Updated Category News Views 56

Stepping into 2026, the buzz in enterprise finance isn’t about a new gadget or slick marketing trick; it's about complex financial processes being tamed by artificial intelligence. Octopus AI is trying to spearhead this transition by automating the intricacies of financial workflows while ensuring that human judgment remains at the helm. The Austin, Texas outfit laid...

Continue Reading

Top 5 Most Recently Viewed Articles

Skyline Medical Faces High Market Pressure with POAI Low at $0.64

Updated Category News Views 93

Skyline Medical Inc. Stock Reaches New Low In the face of a volatile market, Skyline Medical Inc. (POAI) has seen its stock price fall to a concerning 52-week low of $0.64. This sharp decline represents an 81.66% drop over the past year, revealing the significant challenges the company has encountered. Investors are keeping a close watch on POAI's efforts to stabilize...

Continue Reading
Foresight Diagnostics Validates CLARITY MRD Assay for DLBCL

Updated Category News Views 308

Foresight Diagnostics Validates CLARITY MRD Assay for DLBCL Treatment Foresight Diagnostics, a notable player in the diagnostics industry, has shared compelling new findings regarding its CLARITY Minimal Residual Disease (MRD) assay. This groundbreaking information was revealed during a multicenter study focused on frontline Diffuse Large B-Cell Lymphoma (DLBCL). The...

Continue Reading
Surge in Medical Tricorder Demand Drives Market Toward Growth

Updated Category News Views 123

Growing Demand for Medical Tricorders and Future Prospects The medical tricorder market is experiencing significant momentum, with a remarkable valuation of USD 3.7 billion in 2023. This industry is poised for substantial growth, projected to reach USD 6.3 billion by 2032. The compound annual growth rate (CAGR) expected from 2024 to 2032 is approximately 6.1%. The driving...

Continue Reading
Catalis Dental Lab Partners Broadens Reach with New Facility

Updated Category News Views 152

Catalis Dental Lab Partners Expands with New Acquisitions Catalis Dental Lab Partners has reached two significant milestones in its expansion efforts. The company announced the acquisition of Revolution Dental Lab and the launch of a cutting-edge Digital Design Center focused on servicing dental professionals more effectively. Acquisition of Revolution Dental Lab As part...

Continue Reading
Pacific West Bancorp Reports Noteworthy Q2 Financial Achievements

Updated Category News Views 151

Pacific West Bancorp Posts Strong Second Quarter Results Pacific West Bancorp (PWBK), the holding company of Pacific West Bank, recently disclosed its second quarter financial results, revealing a net income of $130 thousand or $0.05 per diluted share. This financial outcome underscores the company's commitment to its growth strategy, as they continue to strengthen their...

Continue Reading